Martina Porter, MD, FAAD, vice chair of research, Department of Dermatology, Beth Israel Deaconess Medical Center, discusses efficacy and safety findings from a phase 2 study.
This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology.
At the American Academy of Dermatology Annual Meeting 2024, Martina Porter, MD, FAAD, vice chair of research, Department of Dermatology, Beth Israel Deaconess Medical Center, reinforced the efficacy and safety profile of twice-daily ruxolitinib (Opzelura) cream 1.5% for patients with mild to moderate hidradenitis suppurativa (HS), according to a phase 2 study (NCT05635838).
AJMC: Can you provide an overview of the late-breaking session you presented, "Efficacy and Safety of Ruxolitinib Cream in Patients With Hidradenitis Suppurativa (Hurley Stage I and II): Results From a Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study?"
Porter: I presented the efficacy and safety of ruxolitinib cream in patients with hidradenitis suppurativa or HS, who are early stage 1 and 2. This was a randomized double-blind vehicle-controlled phase 2 study. The study design was essentially a 16-week double-blind period where patients applied the cream twice daily and it was compared with vehicle. These are all adult patients who had HS for more than 3 months, their abscess and nodule count had to be between 3 and 10, and they couldn't have any draining nodules.
AJMC: What were your primary findings, and did anything surprise you?
Porter: The main outcome was a change from baseline and abscess and inflammatory nodule [AN] count through week 16. That was the primary end point. We also looked at percentage change in the AN counts and the highest score in the International Hidradenitis Suppurativa 4.
Nothing, I would say, is very surprising. The things that were great were that there actually was a statistically significant difference between the vehicle and the ruxolitinib cream, favoring the ruxolitinib cream, and we saw the changes as early as week 8 of the 16-week period. When we're looking at the proportion of patients who achieved a 50% or 75% improvement, there were significant changes as well between the vehicle and the cream. There was still a numerical difference in the 90% and 100% improvement, but less so.
AJMC: Can you discuss the safety profile of these findings and if there were any notable adverse events?
Porter: Overall, the ruxolitinib cream was very well tolerated in the first 16 weeks. There were no serious treatment-emergent adverse events [AE], and there were about 35 patients in each group. About 40% of patients had an AE, which is not surprising for a study of this length. But there was only 1 grade 3 or higher and serious AE, and that was in the vehicle group. It was a patient who had diabetic ketoacidosis.
AJMC: How do the results of this study contribute to our understanding of the potential role of ruxolitinib cream as a treatment option for mild to moderate HS compared with existing therapies?
Porter: I think the exciting part is that this is the very first study that we've done from an industry-funded standpoint that was a double-blind study for patients who had milder HS disease. And so, it's nice that we saw some statistically significant results. Things I think that are still to be determined is what type of end point we'll use for a trial like this, because patients overall are less severe and the end points we've always historically used are for patients who have moderate to severe disease.
But like I said, the promising things are this study was very popular among patients that are clearly looking for more treatment options, both topical and for people who have less severe disease.
AJMC: Given the lack of approved therapies for mild-to-moderate HS and the limitations of current standard of care, how do you envision ruxolitinib cream fitting into the treatment landscape for this condition, particularly in terms of patient quality of life and long-term management?
Porter: In general, you know that patients with HS who even have mild disease have very significant quality of life impairments. This trial was looking at monotherapy, so patients aren't allowed to be on any other treatments while they use the ruxolitinib cream. But my suspicion is that in clinical practice, this could be used as monotherapy for patients who have a milder disease, but it can also be used as adjunctive therapy for patients who have moderate-to-severe disease since we don't see those patients clearing up entirely with the available treatments that are out there right now or approved.
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces as AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces as AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
2 Commerce Drive
Cranbury, NJ 08512